Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

Phase 4 Completed 39 enrolled United Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.

Timeline

Start: 2012-04
Primary completion: 2014-03
Completion: 2014-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Treprostinil	Other / unclassified	30 unknown	Subcutaneous

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

Summary

Timeline

Drugs

Indications